Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape - PubMed
7 hours ago
- #relapsed/refractory MM
- #multiple myeloma
- #selinexor
- Selinexor is a first-in-class, orally bioavailable selective inhibitor of exportin 1 (XPO1) used in multiple myeloma (MM) treatment.
- It has shown efficacy in relapsed/refractory MM, particularly in combination with other agents like bortezomib-dexamethasone and dexamethasone.
- Selinexor-based therapies are effective across various patient subgroups, including those with triple-class refractory disease, renal dysfunction, and high-risk cytogenetics.
- The drug is a valuable option for patients ineligible for T-cell-redirecting therapies or difficult-to-treat subgroups.
- Ongoing research aims to optimize selinexor's use, mitigate toxicities, and improve treatment adherence in MM.
- Further data is awaited to clarify selinexor's role in different treatment settings and address unmet clinical needs.